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• Animals have been, are and will constitute an important  
source of infectious diseases for humans:
− About half of the human pathogens are zoonotic and 
9% are emerging
− The three most devastating pandemics in history 
were zoonotic (Plague, Spanish Influenza, HIV/AIDS)
− About 75% of the recent emerging pathogens are 
zoonotic (WNV, SARS, Nipah/Hendra, ...)
• Overall, zoonotic pathogens are more than 3 times 
more likely to be associated with emerging diseases 
than non-zoonotic pathogens.
Infectious diseases: Human-Animal Interface
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Transmission
• Zoonotic transmission includes:
– Wildlife reservoirs transmitting directly to humans: 
rabies, West Nile virus…
– Transmission from a wildlife reservoir to humans via 
domestic animals: influenzas, rabies, Hendra and 
Nipah, brucellosis, tuberculosis
– Transmission to humans via the Food chain (Food 
Safety): salmonella, E. coli O157, 
(Lloyd-Smith J.O. et al. (2009) Science 326: 1362-1367
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J. O.  Lloyd-Smith et al.,  Science  326, 1362-1367 (2009)
Diagram of zoonotic transmission dynamics
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Emergence of new agents
• Increased global travel: e.g. influenza’s –
Avian/swine
• Relaxation of veterinary regulations: e.g. EIV 
outbreak in Australia in 2007
• Unpredictable effects of climate change: 
Bluetongue virus outbreak in Europe
• Urbanization and change in animal husbandry: 
HSF, PRRS and PCV-2 in swine
• The threat of intentional release…
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The example of Nipah/Hendra
• Hendra and Nipah viruses are newly discovered zoonotic viruses first 
isolated from outbreaks in Australia (1994) and Malaysia (1998)
• The viruses are closely related and member of the paramyxoviridae
family, genus Henipahvirus. 
• The viruses cause severe disease in a variety of animal species, 
including humans, horses, pigs, dogs and cats  
• Both viruses are classified as BSL-4 
pathogens and Nipah is on the list of
select agents by the USDA
Eaton et al, 2006. Nature Reviews Microbiology
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Hendra outbreaks
• In September 1994, an outbreak of acute respiratory 
disease occurred in a group of horses outside Brisbane
• 20 horses affected: 14 died (6 euthanized)
• Horses were tachypnoeic, tachycardic, ataxic, frothy 
nasal discharge, collapse – 7 deaths within 12 hours, 
(10 < 36 hours) 
• Two people nursing the index case became infected, 1 
died
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Hendra outbreaks
• Since 1994, Hendra has caused a few sporadic outbreaks in 
Australia, ie a total of 14 reported outbreaks involving ~40 
horses and 7 humans
− Case-fatality rate in horses: 80%
− Case-fatality rate in humans: 57%. One patient presenting 
relapsed encephalitis long after the initial infection 
• Equine cases occur mainly late winter/spring. Horse to horse 
transmission is not easy
• All human cases associated with close contact with affected 
horses (endoscopy, treating, nursing or post-mortem 
examination). Extremely low risk handling normal horses
• No human-to-human transmission reported
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Nipah outbreaks
• Nipah emerged in 1998 in Malaysia and caused widespread 
panic because of the high mortality rate (40%) in people and 
the inability to control the disease initially.  
• Pigs were the apparent source of infection among most 
human cases (farmers, abattoir workers). Pigs were 
frequently asymptomatic (silent spreaders)
• Subsequent outbreaks in Malaysia, India and Bangladesh in 
2000-2008
• Human case-fatality rate 40-75%
• Human-to-human transmission of Nipah virus and no obvious 
direct link to infected livestock reported in later outbreaks.
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Nipah Field Investigations - Malaysia
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• Limited in geographic extension, but….
• The Malaysian outbreak caused considerable 
social disruptions and tremendous economic 
loss to an important pig industry.
– Nearly 1 million pigs culled (58 M$)
– Loss of the capital infrastructure on farms
– Loss of employment - 36,000 jobs
– Loss of export income - 120 M$
The Impact of the Outbreak
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Where did the virus come from?
• Pteropid bats (fruit bats) are believed to be the natural 
reservoir hosts. Different bat species for Nipah and Hendra 
• Seroprevalence varies between bat colonies (2–50%).
Suggests non-lethal infection in bats
• Detected in bat secretions (abortions & urine)
• No definitive data on bat-to-bat spread
• Spill-over transmission to pigs/horses is likely 
to occur through contaminated water and feed
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Global Distribution of fruit bats
Courtesy: CSIRO
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2007: 1 horsePeachester 2006: 1 horse
Murwillambah 2006: 1 horse
Brisbane 2008: 5 horses, 2 humans
Cannonvale 2008: 1 horse
Brisbane 1994: 20 horses, 2 humans
Mackay 1994: 1 horse, 1 human
Cairns 1999: 1 horse 2004: 1 horse, 1 human
Townsville 2004: 1 horse
Rockhampton 2009: 3 horses, 1 human
• Antibody to Hendra has been detected in all 4 species of fruit bats 
indigenous to Australia. Equine cases occur mainly late winter/spring  
Associated with bat breeding season?
• Influx of more than 130.000 bats into Victoria since early 2010 
attributed to wet weather conditions in Queensland
Distribution of outbreaks and bat populations
Courtesy. Gilkerson
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Management of the disease
• The following counter measurements are important
– Surveillance: first line of defense. Very often relies on 
reporting of clinical disease in populations at risk, which is 
not very reliable 
– Culling: stop spread of virus
– Vaccination: no commercial vaccines are available today
– Diagnosis: stall-site (point-of-care) diagnostic tests are 
needed but not yet available 
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Vaccination
• Vaccination remains a primary method for 
the effective prevention and control of 
Nipah/Hendra
• The role of Manufactures for a timely
supply of affordable and fit-for–
purpose vaccines is pivotal
• Key to risk management is communication 
and co-operation through every sector of 
the industry. 
• Several initiatives are ongoing….
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Challenges and constraints
• The development of a human vaccine is likely to be expensive and 
long range making it uneconomical for any pharmaceutical 
company to undertake. Veterinary vaccines should be considered
• Competition for assigned R&D resources
• Need for high containment facilities to develop and produce 
vaccine
• Scale up and transfer to Manufacturing
• Availability of BSL4 animal test facilities for testing of vaccines
The use of well characterized vaccine platforms will 
alleviate some of these issues

















• Adenoviruses (E1 del)
• Herpesviruses (gD del)
DNA vaccines
• Plasmids (Melanoma; WNV)





Technologies having at least one example of registered vaccine
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– The canarypox virus vector originates from an 
attenuated vaccine strain for canaries
– Large genome, easily manipulated and 
genetically stable
– Real technology platform used for commercial 
vaccines in dogs, cats, ferrets and horses and has 
has potential in humans
– Non replicative vector in mammals
The use of ALVAC as a vector
‘’Single hit infection’’
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After vaccination the vector infects and instructs the cell
to produce the protective proteins which in turn are 
presented to the immune system in a way that closely 
mimics natural infection (authentic expression). The 
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ALVAC is a true technology platform
R&D
• Rapid generation of new constructs (strong expertise) 
• No handling of dangerous pathogens (WNV, H5N1, 
NiV..) through the use of synthetic genes
Manufacturing
• Same manufacturing process for all recombinants: 
simple process with high batch-to-batch consistency 
which is easy to scale up
• Standardized batch release test
Regulatory
• Known technology. 
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ALVAC: a commercial success
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Nipah vaccine candidates
• Several vaccine platforms have been tested successfully 
for efficacy in animal models
– Recombinant vaccinia vaccine expressing G or F of NiV 
virus (Guillaume et al. J. Virol. 78, 2004). Regulatory 
acceptance?
– Subunit vaccine containing soluble G protein of NiV 
purified from recombinant vaccinia infected cells 
(Mungall et al. J. Virol. 80, 2006). Scalability?
– Recombinant canarypox (ALVAC) vaccine expressing G 
or F of NiV virus
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Proof of concept ALVAC-NiV constructs
• Pigs were vaccinated twice IM at 14 days interval and 




Treatment groups (4 pigs per group)
1 ALVAC F
2 ALVAC G 10E8 PFU/construct
3 ALVAC G + F
4 Controls
ALVAC-G ALVAC G + FALVAC-F
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Virus Isolation Post-Challenge (PFU/ml)
• Vaccination led to the development of 
high antibody levels
• Vaccination with ALVAC-NiV prevented 
virus replication and virus shedding
• Combined vaccination with both G and F 
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Conclusions
• Zoonotic pathogens constitute an important risk for emerging 
diseases in man
• Vaccination, together with management measures, remains the 
primary method for the effective prevention and control of 
emerging diseases
• Well established vaccine platforms will facilitate development and 
reduce time to market 
• The example of Nipah/Hendra shows that effective control is the 
shared responsibility of Governments, Industry and stake holders
• An effective vaccine against Nipah/Hendra is within reach….
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